MCK SEC Filings

McKesson Corporation reported strong financial performance for the period ending December 30, 2025. Total revenues saw a significant increase of 11% for the quarter and 15% for the nine-month period compared to the prior year, driven by robust growth in the North American Pharmaceutical and Oncology & Multispecialty segments. Diluted earnings per share (EPS) also showed substantial improvement, rising to $9.59 for the quarter and $24.73 for the nine months, reflecting a 38% and 57% increase, respectively. The company completed two strategic acquisitions during the period: PRISM Vision Holdings, LLC for $875 million and Community Oncology Revitalization Enterprise Ventures, LLC for $2.5 billion, both aimed at strengthening its Oncology & Multispecialty segment. These acquisitions, along with a renewed focus on operational efficiencies, are expected to contribute to future growth. McKesson also continued its capital return program, repurchasing $2.1 billion in common stock and increasing its quarterly dividend to $0.82 per share.

McKesson Corporation (MCK) has filed a Current Report on Form 8-K to announce preliminary financial results for the quarter ended December 31, 2025. The report indicates that the company is providing an update on its operational and financial performance for the specified period, with detailed information expected to be found in the attached earnings release (Exhibit 99.1). This filing serves as an early disclosure of key metrics and financial condition for the third fiscal quarter of 2026.

McKesson Corporation reported robust financial performance for the second quarter and first half of fiscal year 2026. Revenues saw a significant increase of 10% and 16% year-over-year for the respective periods, driven by strong growth in the North American Pharmaceutical and Oncology & Multispecialty segments. Diluted Earnings Per Share (EPS) surged to $8.92 in Q2 and $15.16 for the first half, up substantially from the prior year, reflecting improved profitability. The company completed two significant acquisitions during the period, PRISM Vision Holdings, LLC and Community Oncology Revitalization Enterprise Ventures, LLC, further expanding its healthcare services capabilities. Despite increased investments in acquisitions and ongoing restructuring initiatives, McKesson demonstrated effective cost management, with total operating expenses decreasing by 20% and 9% for the quarter and half-year, respectively. The company also returned significant capital to shareholders through share repurchases ($1.4 billion in the first half) and a dividend increase. While facing some operational challenges, such as a provision for bad debts related to Rite Aid's bankruptcy, McKesson's strategic acquisitions and solid operational execution position it for continued growth and value creation for its investors.

McKesson Corporation (MCK) has filed a Form 8-K to report its preliminary financial results for the quarter ended September 30, 2025. The key information is contained within the earnings release furnished as Exhibit 99.1 to this filing. Investors should refer to this exhibit for detailed financial performance data, including revenue, earnings, and any significant operational updates for the second fiscal quarter.

McKesson Corporation (MCK) announced an update to its Fiscal Year 2026 guidance and long-term financial targets during its Investor Day on September 23, 2025. This filing provides investors with forward-looking information regarding the company's strategic objectives and expected financial performance. The details of these updates were disseminated via a press release, which is attached as an exhibit to this 8-K filing, and further elaborated during the Investor Day event, including a live webcast and accompanying presentation accessible on McKesson's Investor Relations website. Investors should pay close attention to the revised guidance and long-term targets as they reflect management's current outlook on the company's growth prospects and operational performance. The information furnished in this report, while not deemed 'filed' for certain regulatory purposes, offers crucial insights into McKesson's strategic direction and financial trajectory, enabling investors to make more informed decisions.

McKesson Corporation (MCK) has announced a significant restructuring of its reportable business segments, effective in the second quarter of fiscal year 2026. The company will now report financial results across four primary segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. This change reflects the company's strategic allocation of resources and performance assessment by its Chief Operating Decision Maker. Notably, the Medical-Surgical Solutions segment is slated for separation into an independent company, as previously announced in May 2025. In addition to segment realignments, McKesson is progressing with the sale of its Norwegian operations, having entered into a definitive agreement. The company has also filed supplemental historical financial information, restated under the new segment structure, to provide investors with a clearer view of historical performance across these redefined segments. These changes, while impacting reporting, do not retroactively alter previously issued consolidated financial statements or historical earnings per diluted share.

McKesson Corporation reported strong revenue growth of 23% for the second quarter of fiscal year 2025, reaching $97.8 billion, primarily driven by its U.S. Pharmaceutical segment. Despite this top-line expansion, net income attributable to McKesson Corporation saw a decrease of 14% to $784 million, resulting in diluted earnings per share of $6.25, down from $7.00 in the prior year period. This decline is partly attributed to a $189 million provision for bad debts related to the Rite Aid bankruptcy and increased operating expenses associated with recent significant acquisitions. The company completed two major acquisitions during the quarter: PRISM Vision Holdings, LLC for $874 million and Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for $2.5 billion. These acquisitions, along with increased investments in technology, contributed to a rise in operating expenses and a significant use of cash in investing activities. McKesson also returned $671 million to shareholders through share repurchases and dividends, and announced an increase in its quarterly dividend to $0.82 per share.

McKesson Corporation (MCK) has filed an 8-K report on August 5, 2025, to disclose preliminary financial results for the quarter ended June 30, 2025. The report primarily serves to attach the earnings release dated August 6, 2025, which contains the detailed financial information for the period. Investors should refer to Exhibit 99.1 for the specific operational and financial performance figures. While the filing itself is procedural and furnished rather than formally filed, the attached earnings release is the critical document for understanding McKesson's recent performance. Investors are encouraged to review the preliminary results to gauge the company's progress and its impact on the overall financial outlook. The filing does not contain new material events beyond the reporting of these preliminary results.

McKesson Corporation (MCK) has filed an 8-K report detailing the results of its Annual Meeting of Shareholders held on July 30, 2025. The report indicates strong shareholder support for the company's slate of director nominees, with all individuals elected to the Board of Directors by a significant majority of votes cast. Additionally, shareholders overwhelmingly ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the upcoming fiscal year, signaling confidence in the company's financial oversight. The advisory vote on executive compensation also passed, suggesting general shareholder approval of the current compensation structure for named executive officers.

McKesson Corporation (MCK) has filed a Form 8-K on June 9, 2025, to provide an update on its Fiscal Year 2026 financial outlook ahead of investor meetings. The key takeaway for investors is the upward revision of the company's full-year Adjusted Earnings per Diluted Share (Adjusted EPS) guidance. McKesson now expects Adjusted EPS to be in the range of $36.90 to $37.70, an increase from the previously announced range of $36.75 to $37.55. This positive adjustment signals continued confidence in the company's performance and its ability to generate shareholder value. The company also reaffirmed its full-year effective tax rate guidance of 17% to 19%. The filing details a projected effective tax rate for the first half of the fiscal year between 17% and 20% (with a higher rate in Q1 than Q2), and for the second half between 16% and 19%. All other guidance provided on the May 8, 2025 earnings call remains in effect. McKesson emphasizes that Adjusted EPS is a non-GAAP measure and provides context regarding its forward-looking guidance for this metric, noting the difficulty in reconciling it to GAAP figures.

McKesson Corporation (MCK) has announced the successful closing of a significant notes offering, raising a total of $2.0 billion. This offering comprises three tranches of senior notes: $650 million in 4.650% Notes due 2030, $650 million in 4.950% Notes due 2032, and $700 million in 5.250% Notes due 2035. The net proceeds from this issuance are earmarked for a strategic acquisition, specifically the purchase of a 70% controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC. This move indicates McKesson's commitment to expanding its presence and capabilities within the oncology services sector.

McKesson Corporation's fiscal year 2025 performance demonstrated robust revenue growth, up 16% year-over-year, driven primarily by its U.S. Pharmaceutical segment, which saw increased volumes from retail national accounts and growth in specialty pharmaceuticals. The company also reported a significant increase in diluted earnings per share from continuing operations to $25.72, up from $22.39 in the prior year. Key financial events impacting the year included a $667 million charge related to the sale of its Canadian retail businesses and $298 million in restructuring charges for enterprise-wide efficiency initiatives. McKesson returned $3.5 billion to shareholders through share repurchases and dividends, underscoring its commitment to capital return. The company is actively managing significant legal and regulatory challenges, particularly those related to opioid litigation, for which it has accrued $6.4 billion in liabilities. While these are ongoing, the company's core pharmaceutical distribution and technology solutions segments appear to be performing well, evidenced by the revenue and EPS growth. Strategic investments in technology and ongoing efforts to drive operational efficiencies are key focus areas for future performance.

McKesson Corporation (MCK) has filed an 8-K report on May 7, 2025, to announce preliminary financial results for the fiscal quarter and year ended March 31, 2025. The key information is contained within an earnings release attached as Exhibit 99.1, which provides the company's performance metrics for the period. Investors should refer to this exhibit for detailed financial figures and operational updates. While the 8-K itself is a notification of these preliminary results, the substance of the disclosure is in the accompanying earnings release. This filing serves as a timely update to the market ahead of the official reporting period, offering insights into McKesson's financial condition and operational results. The company is furnishing this information, meaning it's not deemed 'filed' for certain SEC purposes but is still a crucial communication to stakeholders.

McKesson Corporation reported strong revenue growth for the third quarter and first nine months of fiscal year 2025, driven by its U.S. Pharmaceutical segment and increased volumes in its International segment. Diluted Earnings Per Share (EPS) saw a significant increase in the third quarter, though it slightly declined year-over-year for the nine-month period. The company also completed the divestiture of its Canadian retail businesses. Significant charges related to restructuring initiatives and remeasuring the Canadian retail disposal group to fair value were incurred. McKesson continues to manage its substantial opioid-related litigation liabilities, with significant payments made and a large accrued liability remaining. The company's financial position remains solid, supported by robust operating cash flow and access to credit facilities. McKesson continues to return capital to shareholders through dividends and substantial share repurchases, with a significant remaining authorization. Strategic acquisitions, including a controlling interest in PRISM Vision Holdings, are underway to further enhance its business segments. Investors should monitor ongoing litigation developments, particularly those related to opioids, and the integration of new acquisitions.

McKesson Corporation (MCK) has filed a Form 8-K on February 5, 2025, to report preliminary results for the quarter ended December 31, 2024. While this filing provides an update on the company's financial performance, it's important to note that the information is furnished and not deemed 'filed' for certain regulatory purposes, meaning it doesn't automatically get incorporated into other SEC filings unless specifically referenced. Investors should refer to the attached earnings release (Exhibit 99.1) for the specific details of these preliminary results. This report serves as a notification mechanism for the market regarding McKesson's recent financial outcomes. The key details regarding revenue, profitability, and any significant operational developments will be found within the accompanying earnings release. Investors are encouraged to review this document to understand the company's performance trajectory and its implications for future financial health.

McKesson Corporation filed an 8-K/A amendment on February 5, 2025, providing updated information related to its preliminary results for the quarter ended December 31, 2024. While the filing itself doesn't contain the detailed financial figures, it references an attached earnings release (Exhibit 99.1) dated February 5, 2025, which is the primary source for this quarterly update. Investors should refer to this earnings release for specifics on the company's financial performance, operational highlights, and forward-looking statements for the period.

McKesson Corporation reported its financial results for the second quarter and first half of fiscal year 2025. Total revenues saw a significant increase of 21% for the quarter and 14% for the six-month period, driven by growth in the U.S. Pharmaceutical segment and increased pharmaceutical distribution volumes internationally. However, diluted earnings per share decreased substantially, reflecting higher operating expenses and specific charges. Key items impacting the results include a substantial charge of $643 million related to the remeasurement of the Canadian retail disposal group to fair value less costs to sell. Additionally, the company incurred $227 million in restructuring charges for enterprise-wide technology modernization initiatives. The company also continues to manage its significant estimated liability for opioid-related claims, totaling $6.4 billion as of period end. Despite the earnings decline, McKesson demonstrated strong operational cash flow and continued to return capital to shareholders through share repurchases ($2.0 billion in the first half) and a raised quarterly dividend. The company also announced a significant acquisition in the oncology sector, pending regulatory approval.

McKesson Corporation (MCK) has filed an 8-K on November 5, 2024, to report preliminary financial results for the quarter ended September 30, 2024. The filing primarily serves to attach the earnings release (Exhibit 99.1) which contains the detailed operational and financial condition information. Investors should refer to Exhibit 99.1 for the specific financial metrics and performance details.

McKesson Corporation (MCK) has announced the successful closing of a $500 million offering of 4.250% Notes due 2029. The net proceeds, approximately $498 million after underwriting discounts but before expenses, are intended to be used, along with existing cash, to fund the redemption of its 5.250% notes due February 15, 2026. This move signals a proactive approach to managing its debt structure, likely aiming for lower interest costs or extended maturity profiles. The company also issued a notice of redemption for its outstanding 2026 Notes. This refinancing activity is a significant event for investors, indicating capital allocation strategies and potential shifts in McKesson's financial leverage and interest expense. Investors should monitor the impact of this new debt on the company's balance sheet and future earnings.

McKesson Corporation (MCK) filed an 8-K on September 5, 2024, to provide an update following its participation in the Wells Fargo 2024 Healthcare Conference. The primary takeaway for investors is that McKesson reaffirmed its full-year fiscal 2025 Adjusted Earnings per Diluted Share (EPS) guidance, which remains in the range of $31.75 to $32.55. This affirmation suggests confidence in the company's ongoing performance and its ability to meet previously stated financial targets for the fiscal year. Additionally, the company provided an anticipated range for its second quarter fiscal 2025 Adjusted EPS, projecting it to be between $6.70 and $7.00. This forward-looking statement offers investors a more immediate financial outlook, signaling expected earnings within the current fiscal quarter. The filing also includes standard disclosures regarding non-GAAP financial measures and cautionary statements about forward-looking information, reminding investors of the inherent risks and uncertainties that could impact actual results.

McKesson Corporation (MCK) has announced a significant strategic move with the signing of a definitive agreement to acquire a controlling interest (approximately 70%) in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures) for approximately $2.49 billion in cash. Core Ventures serves as the exclusive provider of non-clinical business and administrative services to Florida Cancer Specialists & Research Institute, LLC, a prominent oncology practice. This acquisition signals McKesson's deepening commitment to the oncology sector and its strategy to expand its services beyond traditional pharmaceutical distribution into integrated healthcare solutions. The transaction is subject to customary closing conditions, including regulatory review, and is expected to enhance McKesson's capabilities in supporting oncology practices. Investors should note that the company has included cautionary statements highlighting potential risks and uncertainties associated with this acquisition, such as obtaining regulatory approvals, achieving expected outcomes, and potential adverse impacts from integration challenges or external events. The full details of the news release are available on McKesson's website.

McKesson Corporation reported total revenues of $79.3 billion for the fiscal second quarter ended June 30, 2024, a 6% increase compared to the prior year. This growth was primarily driven by its U.S. Pharmaceutical segment, benefiting from market growth in specialty pharmaceuticals and higher volumes. Despite revenue growth, net income attributable to McKesson Corporation saw a slight decrease to $915 million, or $7.00 per diluted share, down from $958 million, or $7.02 per diluted share, in the same period last year. This decline was influenced by increased operating expenses, particularly higher claims and litigation charges related to opioid settlements, and a decrease in gross profit margin. The company repurchased $528 million of its common stock and paid $82 million in dividends during the quarter, underscoring its commitment to returning capital to shareholders, with an additional $4.0 billion authorization for share repurchases approved in July 2024.

McKesson Corporation (MCK) has filed an 8-K report on August 7, 2024, to announce its preliminary results for the first quarter ended June 30, 2024. The report primarily references an attached earnings release (Exhibit 99.1) which contains the detailed financial performance for the period. Investors should refer to this earnings release for specific operational and financial metrics, as the 8-K itself is largely a notification of this information being made public.

McKesson Corporation (MCK) filed an 8-K report detailing the results of its Annual Shareholders' Meeting held on July 31, 2024. The primary outcomes of the meeting include the overwhelming re-election of all director nominees proposed by the Board, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2025, and the approval of advisory votes on executive compensation and an amendment to the company's Certificate of Incorporation for officer exculpation. Notably, two shareholder-submitted proposals, one concerning an independent chairman and another requesting a report on the risks of state policies restricting reproductive healthcare, were not approved by the shareholders. These voting outcomes suggest strong shareholder confidence in the current Board of Directors and the company's financial oversight and governance practices, while also indicating a divergence of opinion on specific social and governance issues.

McKesson Corporation (MCK) announced a board composition change through an 8-K filing. The company has elected Deborah Dunsire, M.D., to its Board of Directors, effective June 3, 2024. Dr. Dunsire brings extensive experience in the biopharmaceutical and oncology sectors, having previously served as CEO of H. Lundbeck A/S and holding various leadership roles in other pharmaceutical companies. Her appointment is expected to enhance the Board's expertise in relevant industries. In addition, McKesson disclosed that two current directors, Linda Mantia and Susan R. Salka, will not be standing for re-election at the upcoming 2024 annual meeting of shareholders. Their terms will expire at that meeting. These changes signal a refresh in the Board's composition, bringing in new strategic perspectives while transitioning out existing members.

McKesson Corporation (MCK) has filed its 10-K for the fiscal year ended March 30, 2024, detailing its performance as a diversified healthcare services leader. The company reported increased revenues, primarily driven by its U.S. Pharmaceutical segment, which benefited from growth in specialty pharmaceuticals and higher volumes. However, diluted earnings per share saw a decrease compared to the prior year, impacted by a significant provision for bad debts related to the bankruptcy of its customer, Rite Aid. Mckesson continues to manage various legal and regulatory matters, including significant opioid-related litigation, which resulted in a substantial charge for the current fiscal year. Despite these challenges, the company returned considerable capital to shareholders through share repurchases and dividends, underscoring its commitment to shareholder value. The company also highlighted its ongoing investments in technology and operational efficiencies across its four main business segments: U.S. Pharmaceutical, Prescription Technology Solutions, Medical-Surgical Solutions, and International.

McKesson Corporation (MCK) filed an 8-K on May 7, 2024, to report its preliminary financial results for the fiscal year and fourth quarter ended March 31, 2024. While the full details are contained within an attached earnings release (Exhibit 99.1), this filing serves as an announcement of these results. Investors should refer to the earnings release for comprehensive financial data, performance metrics, and management commentary. This report does not contain newly filed financial statements but rather furnishes information that is typically released through earnings announcements. The information is furnished and not deemed 'filed' for the purposes of Section 18 of the Exchange Act, meaning it doesn't automatically become incorporated into prior SEC filings unless explicitly stated. Investors will need to consult the earnings release directly for the substantive financial information.

McKesson Corporation reported an increase in revenues for the third quarter and first nine months of fiscal year 2024, driven by strong performance in its U.S. Pharmaceutical segment, particularly in specialty pharmaceuticals and retail national accounts. Despite revenue growth, gross profit saw a slight decrease due to the impact of the European divestiture and increased operating expenses. Diluted earnings per share from continuing operations experienced a significant decline year-over-year, largely influenced by a substantial provision for bad debts related to the bankruptcy of its customer, Rite Aid. The company's financial position remains solid, with active capital allocation strategies including significant share repurchases and dividend payments. McKesson is managing its debt effectively and has a substantial remaining authorization for stock buybacks. However, investors should note the ongoing legal proceedings, particularly those related to opioid litigation, which represent a significant contingent liability. The company continues to navigate these challenges while focusing on operational efficiencies and strategic growth.

McKesson Corporation (MCK) filed an 8-K on February 7, 2024, to report preliminary results for the quarter ended December 31, 2023. The filing itself primarily serves as a notification of the release of earnings information, attaching the detailed earnings release as Exhibit 99.1. Investors should refer to the accompanying earnings release for the specific financial performance metrics and operational updates for the third fiscal quarter of 2024. While this 8-K does not contain extensive details itself, its purpose is to make the earnings release publicly available through an SEC filing. This ensures timely disclosure of the company's financial condition and results of operations to the market. Investors are encouraged to review the attached Exhibit 99.1 for a comprehensive understanding of McKesson's performance during the reported period, including key financial figures and management's commentary.

McKesson Corporation (MCK) announced a significant addition to its Board of Directors with the election of Kevin Ozan, effective January 8, 2024. Mr. Ozan brings extensive financial expertise, having served as Executive Vice President and Chief Financial Officer at McDonald's Corporation for seven years, and prior experience in audit and mergers and acquisitions at Ernst & Young. His appointment to the Board's Audit and Finance Committees suggests a continued focus on financial oversight and strategic financial planning. Beyond the board changes, the company also issued a press release on January 9, 2024, highlighting this director election, upcoming participation in the J.P. Morgan Healthcare Conference, and an acquisition of Compile. Investors should note that while the director election is a material event, the details of the press release, including the acquisition and conference participation, are furnished and not deemed 'filed' under SEC regulations, meaning they don't carry the same legal implications as a fully filed document. However, they provide timely insights into the company's strategic direction and activities.

McKesson Corporation (MCK) has filed an 8-K report detailing the extension of its revolving credit facility's maturity date. On November 7, 2023, the company received acknowledgment and consent from Bank of America, N.A. (as administrative agent), lenders, and letter of credit issuers to extend the maturity date from November 7, 2027, to November 7, 2028. This extension provides McKesson with an additional year of access to its revolving credit facility without altering other terms of the existing Credit Agreement. This proactive measure likely signals the company's intent to maintain financial flexibility and a stable liquidity position, which is generally viewed positively by investors, especially in the current economic climate. The company previously disclosed details of this Credit Agreement in its Form 8-K filed on November 7, 2022.

McKesson Corporation reported strong revenue growth for the first six months of fiscal year 2024, with revenues increasing by 10% to $151.7 billion compared to the prior year period. This growth was primarily driven by the U.S. Pharmaceutical segment, which saw higher volumes and price increases, as well as growth in the Prescription Technology Solutions segment. However, net income attributable to McKesson Corporation decreased by 4% to $1.62 billion for the six-month period, resulting in diluted earnings per share of $11.95, a slight increase from $11.68 in the prior year. The decrease in net income was impacted by a significant provision for bad debts related to Rite Aid's bankruptcy and a notable discrete tax benefit in the prior year. The company continues to manage substantial opioid-related litigation liabilities, with an accrued liability of $6.6 billion as of September 30, 2023. McKesson demonstrated a commitment to returning capital to shareholders, repurchasing $1.5 billion in common stock and paying $149 million in dividends during the first six months of fiscal year 2024. The company also increased its quarterly dividend and maintained a substantial remaining authorization for share repurchases, signaling confidence in its ongoing financial health and future prospects.

McKesson Corporation (MCK) filed an 8-K on November 1, 2023, primarily to report preliminary financial results for the quarter ended September 30, 2023, and to announce a key executive leadership transition. While specific financial figures are not detailed within the 8-K itself, the filing indicates that detailed results are available in an accompanying earnings release (Exhibit 99.1). Investors should refer to this release for performance metrics, revenue, and profitability updates for the recent quarter. The most significant leadership change disclosed is the upcoming retirement of Chief Legal Officer Lori A. Schechter, effective as of the date of the notice (October 27, 2023). The company also announced that Michele Lau is expected to succeed Ms. Schechter in this critical role. This transition in legal leadership is an important factor for investors to consider regarding corporate governance and strategic execution.

McKesson Corporation (MCK) has filed an 8-K to address the bankruptcy filing of its customer, Rite Aid. The company states that Rite Aid's bankruptcy is not expected to have a material impact on McKesson's fiscal year 2024 Adjusted Earnings Per Diluted Share outlook, which was previously provided on August 2, 2023. Furthermore, McKesson does not anticipate any material impact on its liquidity position or overall operations as a result of this event. Investors are reminded that McKesson will be releasing its second quarter fiscal 2024 financial results after market close on Wednesday, November 1, 2023. A webcast will be available on the company's Investor Relations website for a review of these results. The filing also includes standard cautionary statements regarding forward-looking statements and potential risks, which investors should consider.

McKesson Corporation (MCK) announced a significant leadership realignment within its technology and finance functions. Britt Vitalone, currently Executive Vice President and Chief Financial Officer, will assume expanded responsibilities, adding oversight of the Company's Technology Organization and Mergers & Acquisitions, effective October 3, 2023. This move aims to enhance strategic alignment and consolidate leadership under Vitalone's extensive experience. Complementing this change, Francisco Fraga has been appointed as the new Executive Vice President, Chief Information Officer, and Chief Technology Officer, reporting directly to Vitalone. Fraga's prior experience as Senior Vice President and Chief Information Officer for Pharmaceutical Solutions and Services positions him to integrate technology efforts. This report also notes the departure of Nancy Avila from her role as Executive Vice President, Chief Information Officer and Chief Technology Officer, though she will remain with McKesson through January 1, 2024, to facilitate a smooth transition.

McKesson Corporation (MCK) filed an 8-K on August 2, 2023, to report preliminary results for the quarter ended June 30, 2023. This filing primarily serves as a notification of the earnings release, which is attached as Exhibit 99.1. Investors should refer to Exhibit 99.1 for the detailed financial performance and operational updates for the period. The information furnished in this 8-K is preliminary and provided to the SEC, but it is not considered 'filed' for purposes of Section 18 of the Exchange Act or incorporated into other filings unless explicitly stated. Therefore, investors should rely on the attached earnings release for the substantive financial information and any forward-looking statements.

McKesson Corporation (MCK) reported strong revenue growth of 11% year-over-year for the quarter ending June 29, 2023, reaching $74.5 billion. This increase was primarily driven by robust performance in the U.S. Pharmaceutical segment, benefiting from market growth, higher volumes, and specialty pharmaceutical expansion. Despite flat gross profit, operating expenses saw a 3% decrease, contributing to a significant 24% rise in income from continuing operations to $997 million. Diluted earnings per share (EPS) from continuing operations also saw a substantial increase, growing by 34% to $7.02. The company demonstrated effective capital management, returning $770 million to shareholders through $696 million in stock repurchases and $74 million in dividends. Management also announced an increase in the quarterly dividend and a significant expansion of its share repurchase authorization, signaling confidence in future financial performance. While the company faces ongoing litigation, particularly related to opioid claims, the overall financial health appears solid, supported by consistent revenue generation and disciplined expense management.

McKesson Corporation (MCK) filed an 8-K on July 25, 2023, detailing the results of its Annual Shareholders Meeting held on July 21, 2023. The report indicates that all director nominees proposed by the Board were elected and that Deloitte & Touche LLP was ratified as the independent registered public accounting firm for the fiscal year ending March 31, 2024. Additionally, shareholders approved, on an advisory basis, the compensation of the Company's named executive officers. The meeting also addressed the frequency of advisory votes on executive compensation, with shareholders overwhelmingly favoring an annual vote. However, a shareholder-submitted proposal regarding the ratification of termination pay did not receive approval. Overall, the filing reflects shareholder confidence in the board and executive compensation structure, while also highlighting a specific area of shareholder concern regarding termination pay.

McKesson Corporation (MCK) filed an 8-K on June 15, 2023, detailing the closing of a significant debt offering and the subsequent satisfaction and discharge of a prior debt instrument. The company successfully issued and sold $1 billion in aggregate principal amount of new notes, comprising $400 million of 4.900% Notes due 2028 and $600 million of 5.100% Notes due 2033. This offering was conducted under their existing shelf registration statement and will provide approximately $991.2 million in net proceeds after underwriting expenses. The proceeds from this offering were strategically utilized. A portion was used to fund the repurchase of outstanding 3.796% Notes due 2024 through a concurrent tender offer, and to satisfy and discharge the related indenture. The remaining proceeds are earmarked for general corporate purposes. This move indicates proactive debt management and a refinancing strategy to potentially lower borrowing costs and extend maturity profiles. Investors should note the terms of the new notes, including redemption provisions, covenants, and a change of control provision that includes a repurchase obligation upon a downgrade to below investment grade.

McKesson Corporation (MCK) announced on June 7, 2023, the commencement of a cash tender offer for any and all of its outstanding 3.796% Notes due 2024. This move indicates the company's proactive approach to managing its debt obligations, specifically targeting the $918 million principal amount of these notes that are currently outstanding. The company plans to potentially satisfy and discharge the indenture for these notes if any remain outstanding after the tender offer. This action suggests a strategic debt management strategy, possibly aimed at optimizing its capital structure, reducing interest expenses, or refinancing at more favorable terms. Investors should monitor the outcome of this tender offer and the company's subsequent actions regarding its debt.

McKesson Corporation's (MCK) 2023 10-K filing highlights a year of strategic divestitures and acquisitions, with a notable focus on exiting European operations while strengthening its Prescription Technology Solutions (RxTS) segment. Revenues saw a 5% increase, primarily driven by growth in the U.S. Pharmaceutical segment, which benefited from market growth, specialty pharmaceuticals, and higher branded drug prices. This top-line expansion was partially offset by divestitures in the International segment and unfavorable foreign currency impacts. Despite revenue growth, gross profit experienced a 6% decrease, mainly due to the European divestitures and foreign currency impacts, though this was partially mitigated by gains in specialty pharmaceuticals and generics within the U.S. Pharmaceutical segment. The company demonstrated strong expense management, with total operating expenses decreasing by 28%, largely due to the prior year's significant remeasurement charges related to European divestitures. Diluted earnings per share from continuing operations saw a substantial increase, primarily attributed to the reduced remeasurement charges compared to the prior year and a lower share count resulting from ongoing share repurchase programs. Key strategic moves included the acquisition of Rx Savings Solutions, LLC, to enhance patient affordability and adherence solutions, and the formation of SCRI Oncology, LLC with HCA Healthcare to advance cancer research. The company also returned significant capital to shareholders through share repurchases and increased its quarterly dividend. Investors should monitor the ongoing opioid litigation, which continues to be a significant contingent liability, although the company has made substantial progress on settlements.

McKesson Corporation filed an 8-K on May 8, 2023, to report its preliminary financial results for the fiscal quarter and full fiscal year ended March 31, 2023. While the filing itself primarily serves as a notification and includes the earnings release as an exhibit, it signals the release of key financial performance data for the period. Investors should refer to the accompanying earnings release (Exhibit 99.1) for detailed financial figures, operational performance insights, and forward-looking statements made by the company. This filing is a crucial update for understanding McKesson's recent financial health and its trajectory as it concludes its fiscal year.

This 8-K filing from McKesson Corporation (MCK) details significant amendments to the company's Amended and Restated By-laws, effective April 26, 2023. The changes primarily focus on enhancing the governance framework related to stockholder meetings, the submission of stockholder proposals, and director nominations. Key updates aim to clarify procedures, align with Delaware corporate law, and provide the Board with greater flexibility in managing these processes. These amendments are designed to streamline operations and ensure compliance with evolving regulatory requirements.

McKesson Corporation (MCK) announced the issuance and sale of $500,000,000 aggregate principal amount of its 5.250% Notes due 2026. These unsecured and unsubordinated notes were issued on February 15, 2023, bearing an annual interest rate of 5.250%, with semi-annual interest payments commencing August 15, 2023. The net proceeds from this offering are expected to be approximately $497.8 million, intended for general corporate purposes, which may include debt repayment. Investors should note the terms of redemption, which allow McKesson to redeem the notes under specific conditions including a make-whole premium before February 15, 2024, and at par thereafter. The indenture includes covenants limiting the company's ability to incur certain liens or engage in sale and leaseback transactions, and provides for a repurchase option for noteholders in the event of a change of control coupled with a credit rating downgrade. These notes are being offered under McKesson's existing shelf registration statement.

McKesson Corporation's third quarter of fiscal year 2023 (ending December 30, 2022) showed robust revenue growth of 3% year-over-year, reaching $70.49 billion. This top-line performance was primarily driven by strong market growth in the U.S. Pharmaceutical segment, fueled by increased drug utilization, new product launches, and price adjustments. However, gross profit saw a 7% decrease due to a higher mix of lower-margin business, particularly from the divested International segment and unfavorable foreign currency impacts. The company made significant strategic moves, including the acquisition of Rx Savings Solutions for $600 million (plus contingent consideration) to bolster its Prescription Technology Solutions segment, and the formation of an oncology research business with HCA Healthcare. Simultaneously, McKesson continued its strategic divestitures by completing the sale of its European Union disposal group. These actions underscore McKesson's focus on optimizing its portfolio and strengthening its core businesses. Despite revenue growth, the company's net income attributable to McKesson Corporation experienced a substantial increase to $1.08 billion from a loss of $7 million in the prior year period, largely due to significant favorable adjustments related to prior year European divestiture charges and a lower share count from active share repurchase programs.

McKesson Corporation (MCK) filed an 8-K on February 1, 2023, to report preliminary results for the quarter ended December 31, 2022. The filing primarily serves as a vehicle to furnish the company's earnings release, which is attached as Exhibit 99.1. Investors should note that this information, while provided to the SEC, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it automatically incorporated into other SEC filings unless specifically referenced. The key details of McKesson's quarterly performance are within the attached earnings release, which this 8-K directs investors to.

McKesson Corporation (MCK) announced the entry into a new Credit Agreement, establishing a New Revolving Credit Facility and a New Term Loan Credit Facility. These agreements, effective November 7, 2022, replace the company's previous revolving credit facility. The New Revolving Credit Facility provides up to $4.0 billion in credit and matures in November 2027, extending the term from the previous facility. The New Term Loan Credit Facility offers up to $500 million for delayed draw borrowings and matures in November 2025. Both new facilities maintain the company's total debt to Consolidated EBITDA ratio covenant at 4.00x, with a temporary step-up to 4.50x allowed post-acquisition. Notably, the new revolving facility includes provisions for incorporating Environmental, Social, and Governance (ESG) targets, which could lead to adjustments in facility fees and margins. Funds from these facilities are designated for general corporate purposes. The termination of the prior credit facility is also noted, with no outstanding borrowings at that time.

McKesson Corporation's Q2 fiscal year 2023 (ended September 29, 2022) report shows a significant increase in revenue, primarily driven by growth in its U.S. Pharmaceutical segment, which benefited from market expansion, higher drug utilization, and new product launches. Despite revenue growth, gross profit saw a slight decrease due to factors including divestitures in the International segment and foreign currency fluctuations. The company also reported a substantial increase in diluted earnings per common share from continuing operations, attributed to favorable adjustments from the remeasurement of its EU disposal group and a lower share count resulting from ongoing share repurchases. The company's strategic initiatives, including recent acquisitions like Rx Savings Solutions and the formation of an oncology research business, along with the completion of its EU divestiture, are shaping its future. McKesson continues to prioritize returning capital to shareholders through significant share repurchases and dividend payments, demonstrating a commitment to shareholder value while managing its substantial opioid-related litigation liabilities.

McKesson Corporation (MCK) filed an 8-K on November 1, 2022, to report its preliminary financial results for the quarter ended September 30, 2022. The filing primarily consists of an earnings release, providing investors with an early look at the company's performance during the second fiscal quarter of 2023. This release is furnished to the SEC and not deemed 'filed,' meaning it doesn't carry the same regulatory implications as a formally filed document, though it provides essential operational and financial data. Investors should review the attached earnings release (Exhibit 99.1) for detailed financial metrics, including revenue, profitability, and any forward-looking statements or management commentary. While this 8-K itself is brief, the incorporated earnings release is the critical document for understanding McKesson's recent financial condition and operational results.

McKesson Corporation (MCK) announced a key executive transition in a recent 8-K filing. Tracy L. Faber, Executive Vice President and Chief Human Resources Officer, has announced her retirement, effective December 1, 2022. Ms. Faber is a named executive officer, making this a significant change in the company's senior leadership. In conjunction with this departure, McKesson has appointed LeAnn B. Smith to succeed Ms. Faber as the new Executive Vice President and Chief Human Resources Officer. This leadership change in human resources is effective upon Ms. Faber's retirement. Investors should monitor how this transition impacts the company's HR strategy and employee relations moving forward.